ライフサイエンスコーパス: Mycobacterium avium complex

1 PLICOR MTB positive and culture positive for Mycobacterium avium complex.

2 e closely related organisms and comprise the Mycobacterium avium complex.

3 rugs (1 case), documented contamination with Mycobacterium avium complex (1 case), suspected cross-co

4 l disease (mean number of organs infected by Mycobacterium avium complex 4.1 [SD 0.8] vs 2.0 [1.1], p

5 from 42 patients grew mycobacteria (58 grew Mycobacterium avium complex, 4 grew Mycobacterium kansas

6 The most common species recovered were Mycobacterium avium complex (69 isolates) and Mycobacter

7 Mycobacterium avium complex (72%) and Mycobacterium absc

8 (100%), CD4 cell count less than 200 (84%), Mycobacterium avium complex (73%), and Pneumocystis cari

9 Nearly 60% of positive cultures were for Mycobacterium avium complex, although this ranged by sta

10 73 (4.3%) were positive for mycobacteria (68 Mycobacterium avium complex and 5 M. tuberculosis).

11 One hundred isolates of Mycobacterium avium complex and eight M. simiae isolates

12 portunistic pathogens of HIV disease such as Mycobacterium avium complex and Pneumocystis carinii, we

13 , 14% (1/7) for Cryptococcus, 10% (1/10) for Mycobacterium avium complex, and 4% (3/72) for PCP.

14 ifferent Mycobacterium tuberculosis complex, Mycobacterium avium complex, and Mycobacterium spp. dire

15 ication and hybridization were observed with Mycobacterium avium complex- and/or Mycobacterium paratu

16 Members of the Mycobacterium avium complex are a family of bacteria tha

17 Pneumocystis carinii pneumonia, Mycobacterium avium complex bacteremia, cytomegalovirus,

18 ing the p35 gene hybridized only to DNA from Mycobacterium avium complex, but not to DNAs from other

19 Prophylaxis against Mycobacterium avium complex can safely be withdrawn or w

20 Mycobacterium avium complex cultures, CD4(+) cell counts

21 ttributable to cytomegalovirus retinitis and Mycobacterium avium complex declined over time (p=0.0058

22 HIV-infected patients with untreated Mycobacterium avium-complex diarrhea are associated with

23 Calif.) to detect Mycobacterium gordonae and Mycobacterium avium complex directly in liquid medium fl

24 Several agents are effective in preventing Mycobacterium avium complex disease in patients with adv

25 Risk of Mycobacterium avium complex disease was examined in huma

26 infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus

27 Azithromycin is active in treating Mycobacterium avium complex disease, but it has not been

28 phylaxis versus withdrawal for prevention of Mycobacterium avium complex disease.

29 We report a case of recurrent disseminated Mycobacterium avium complex (DMAC) disease with anti-gam

30 g the pseudocording, or loose aggregation of Mycobacterium avium complex from M. tuberculosis and the

31 safety of discontinuing prophylaxis against Mycobacterium avium complex has been uncertain.

32 yelitis (patient 1) and disseminated CMV and Mycobacterium avium complex infection (patient 2), respe

33 IS event in HIV-infected patients, unmasking Mycobacterium avium complex infection after starting ant

34 y in which several members have disseminated Mycobacterium avium complex infection.

35 rganism can cause invasive disease mimicking Mycobacterium avium complex infection; recognition and i

36 The Mycobacterium avium complex is a source of disseminated

37 Infection with Mycobacterium avium complex is acquired from the environ

38 A major phenotypic trait of the Mycobacterium avium complex is the ability to produce ro

39 Disseminated infection with Mycobacterium avium complex is the most common opportuni

40 were evaluated for susceptibility testing of Mycobacterium avium complex isolates against clarithromy

41 inically significant isolates included eight Mycobacterium avium complex isolates and one each of Bar

42 ribosomal internal transcribed spacer of 56 Mycobacterium avium complex isolates from pediatric pati

43 g activities seem not to be risk factors for Mycobacterium avium complex lung disease in HIV-negative

44 Mycobacterium avium complex lung disease is an increasin

45 omponent of multidrug treatment regimens for Mycobacterium avium complex lung disease.

46 neumocystis jeroveci pneumonia, disseminated Mycobacterium avium complex, lymphoid interstitial pneum

47 Isolates (119) of the Mycobacterium avium complex (MAC) accounted for 67% of a

48 Whether infection with Mycobacterium avium complex (MAC) among patients with ac

49 e cases, 122 (64%) were culture-positive for Mycobacterium avium complex (MAC) and 69 (36%) for M. ab

50 Of 600 sets tested, 85 (14%) yielded Mycobacterium avium complex (MAC) and 9 (2%) yielded oth

51 In lymphoid tissues coinfected with Mycobacterium avium complex (MAC) and HIV-1, increased v

52 f 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex (MAC) and human dihydrofolat

53 PGE2 production by monocytes infected with Mycobacterium avium complex (MAC) and its effects on int

54 As we have shown for Mycobacterium avium complex (MAC) and Pneumocystis carin

55 s developed for studying macrolide-resistant Mycobacterium avium complex (MAC) and to measure the eff

56 Members of the Mycobacterium avium complex (MAC) are important environm

57 Mycobacterium avium complex (MAC) are opportunistic resp

58 To determine the relationship between Mycobacterium avium complex (MAC) bacteremia and HIV RNA

59 The relationship between Mycobacterium avium complex (MAC) bacteremia and proinfl

60 Patients with AIDS and Mycobacterium avium complex (MAC) bacteremia are at high

61 type 1-infected persons with newly diagnosed Mycobacterium avium complex (MAC) bacteremia were enroll

62 Eight AIDS patients with Mycobacterium avium complex (MAC) bacteremia were random

63 y virus type 1 (HIV-1)-infected persons with Mycobacterium avium complex (MAC) bacteremia, the levels

64 reproducibility of susceptibility testing of Mycobacterium avium complex (MAC) by broth microdilution

65 r antimycobacterial therapy for disseminated Mycobacterium avium complex (MAC) could be withdrawn fro

66 n alone and in combination for prevention of Mycobacterium avium complex (MAC) disease were compared

67 in is a major drug used for the treatment of Mycobacterium avium complex (MAC) disease, but standard

68 Among MSM, the most frequent OIs were Mycobacterium avium complex (MAC) disease, Pneumocystis

69 effective drug regimens for the treatment of Mycobacterium avium complex (MAC) disease.

70 Although opportunistic infections due to Mycobacterium avium complex (MAC) have been less common

71 determine the relationship between levels of Mycobacterium avium complex (MAC) in blood and tissues,

72 Persistent growth of Mycobacterium avium complex (MAC) in the lungs indicates

73 During the terminal stages of AIDS, Mycobacterium avium complex (MAC) infection is the most

74 Mycobacterium avium complex (MAC) infection is the most

75 The relationship between Mycobacterium avium complex (MAC) infection of blood and

76 s conducted in two trials of prophylaxis for Mycobacterium avium complex (MAC) infection to describe

77 ulted from unsuspected local or disseminated Mycobacterium avium complex (MAC) infection.

78 etic diversity and molecular epidemiology of Mycobacterium avium complex (MAC) infections in children

79 cumented history and continued prevalence of Mycobacterium avium complex (MAC) infections.

80 The Mycobacterium avium complex (MAC) is an important cause

81 The Mycobacterium avium complex (MAC) is an important group

82 Lung disease caused by Mycobacterium avium complex (MAC) is increasing in preva

83 Rapid identification of Mycobacterium avium complex (MAC) is possible by use of

84 robiologic cure of AIDS-related disseminated Mycobacterium avium complex (MAC) is possible in patient

85 Mycobacterium avium complex (MAC) is the most common dis

86 Mycobacterium avium complex (MAC) isolates among patient

87 features and outcome of macrolide-resistant Mycobacterium avium complex (MAC) lung disease are not k

88 in prospective macrolide treatment trials of Mycobacterium avium complex (MAC) lung disease were asse

89 household water sources for 36 patients with Mycobacterium avium complex (MAC) lung disease were eval

90 iven Monday, Wednesday, and Friday (TIW) for Mycobacterium avium complex (MAC) lung disease were init

91 cs and to evaluate relapses in patients with Mycobacterium avium complex (MAC) lung disease, but the

92 atment of noncavitary nodular bronchiectatic Mycobacterium avium complex (MAC) lung disease, supporti

93 Organisms within the Mycobacterium avium complex (MAC) may have differential

94 Mycobacterium avium complex (MAC) organisms cause dissem

95 The clinical significance of recovery of Mycobacterium avium complex (MAC) organisms from respira

96 The numbers of isolates of Mycobacterium avium complex (MAC) recovered were 172 (10

97 Species identification of isolates of the Mycobacterium avium complex (MAC) remains a difficult ta

98 Adherence of Mycobacterium avium complex (MAC) to human respiratory e

99 herapeutic outcome in patients infected with Mycobacterium avium complex (MAC) was evaluated.

100 Mycobacterium avium complex (MAC) within macrophages und

101 actors that contribute to protection against Mycobacterium avium complex (MAC), cytokine production b

102 nterleukin (IL)-7 on intracellular growth of Mycobacterium avium complex (MAC), human macrophages wer

103 genetically similar to other members of the Mycobacterium avium complex (MAC), some of which are non

104 y (HAART) on cell-mediated immunity (CMI) to Mycobacterium avium complex (MAC), we measured immune re

105 The most common species recovered were Mycobacterium avium complex (MAC, 73 isolates) and Mycob

106 Organisms in the Mycobacterium avium complex (MAC; M. avium, M. intracell

107 tory pulmonary nontuberculous mycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium absce

108 tis carinii pneumonia [PCP] and disseminated Mycobacterium avium-complex [MAC] infection) in persons

109 ow-growing species, including members of the Mycobacterium avium complex (MAVC).

110 tivity against multiple clinical isolates of Mycobacterium avium complex (MIC's = 0.5-4 micrograms/mL

111 s with Emberger syndrome, monocytopenia with Mycobacterium avium complex (MonoMAC), and MDS.

112 mocystis carinii (n = 26), bacteria (n = 3), Mycobacterium avium complex (n = 2), Nocardia sp. (n = 1

113 Infections caused by organisms of the Mycobacterium avium complex occur in approximately 50 to

114 ia, esophageal candidiasis, and disseminated Mycobacterium avium complex or Mycobacterium kansasii in

115 Ten of 639 MGIT cultures grew Mycobacterium avium complex or Mycobacterium kansasii, h

116 hose previously treated for tuberculosis and Mycobacterium avium complex predominated (27.7% [95% CI:

117 Mycobacterium avium complex pulmonary disease (MAC-PD) i

118 new therapy for Candida esophagitis, whereas Mycobacterium avium complex therapy may be discontinued

119 odes), herpes simplex virus (four episodes), Mycobacterium avium complex (two episodes), and M tuberc

120 Mycobacterium avium complex was concomitantly isolated i

121 c broth dilution test method recommended for Mycobacterium avium complex was modified to develop a re

122 Mycobacterium avium complex was seen in 75% of NTM-posit

123 Isolates of the Mycobacterium avium complex were examined for hemolysin

124 ailable nucleic-acid probes specific for the Mycobacterium avium complex were unreactive for these st